Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
M

Microba Life Sciences Ltd
ASX:MAP

Watchlist Manager
Microba Life Sciences Ltd
ASX:MAP
Watchlist
Price: 0.085 AUD -5.56% Market Closed
Market Cap: AU$51.8m
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

MAP Price Targets Summary
Microba Life Sciences Ltd

Wall Street analysts forecast MAP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MAP is 0.214 AUD with a low forecast of 0.131 AUD and a high forecast of 0.305 AUD.

MAP Lowest Forecast
Wall Street Target
0.131 AUD
54% Upside
MAP Average Forecast
Wall Street Target
0.214 AUD
152% Upside
MAP Highest Forecast
Wall Street Target
0.305 AUD
258% Upside
Lowest
Price Target
0.131 AUD
54% Upside
Average
Price Target
0.214 AUD
152% Upside
Highest
Price Target
0.305 AUD
258% Upside
Microba Life Sciences Ltd Competitors:
Price Targets
YUMC
Yum China Holdings Inc
7% Upside
YUMC
Yum China Holdings Inc
7% Upside

Revenue
Forecast

40% / Year
Past Growth
28% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss
40% / Year
Past Growth
28% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss

For the last 5 years the compound annual growth rate for Microba Life Sciences Ltd's revenue is 40%. The projected CAGR for the next 3 years is 28%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
18%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
18%
Average Beat

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-30%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-30%
Average Miss

What are analyst estimates?

See Also

Summary
MAP intrinsic value, competitors valuation, and company profile.
DCF Valuation
MAP stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MAP stock valuation using valuation multiples.
Wall Street Estimates
MAP price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MAP stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MAP's stock price target?
Price Target
0.214 AUD

According to Wall Street analysts, the average 1-year price target for MAP is 0.214 AUD with a low forecast of 0.131 AUD and a high forecast of 0.305 AUD.

What is Microba Life Sciences Ltd's Revenue forecast?
Projected CAGR
28%

For the last 5 years the compound annual growth rate for Microba Life Sciences Ltd's revenue is 40%. The projected CAGR for the next 3 years is 28%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 318,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.